Breaking News Instant updates and real-time market news.

FGEN

FibroGen

$37.74

-0.03 (-0.08%)

07:14
09/30/19
09/30
07:14
09/30/19
07:14

FibroGen announces publication of results from Phase 2 study of pamrevlumab

FibroGen announced publication in The Lancet Respiratory Medicine of results from the company's PRAISE Phase 2 clinical study of the efficacy and safety of pamrevlumab, a fully human recombinant monoclonal antibody against connective tissue growth factor, for treatment of idiopathic pulmonary fibrosis. The publication, entitled, "Pamrevlumab, an anti-connective tissue growth factor therapy for idiopathic pulmonary fibrosis: a randomized, double-blind, placebo-controlled trial," is available online. In the Phase 2 randomized, placebo-controlled PRAISE study, the decline in percentage of predicted forced vital capacity was significantly lower in the pamrevlumab group than in the placebo group. Specifically, the mean change from baseline to Week 48 in percentage of predicted FVC was -2.9% in the pamrevlumab group compared with -7.2% in the placebo group, which corresponded to a relative reduction in percentage of predicted FVC decline of 60.3% in patients treated with pamrevlumab. Further, the proportion of patients with disease progression was lower in the pamrevlumab group than in the placebo group. The difference between treatment groups was significant at Week 48. The results of this trial indicate that pamrevlumab reduced progression of idiopathic pulmonary fibrosis over a period of one year. Other findings included positive results on multiple efficacy outcomes, including lung function and, for the first time, quality of life and chest imaging with a quantitative high-resolution computed tomography score. Pamrevlumab was well tolerated in this study. Pamrevlumab is currently in Phase 3 clinical development for the treatment of IPF. The ZEPHYRUS study is a randomized, double-blind, placebo-controlled, multi-center trial designed to evaluate the efficacy and safety of pamrevlumab over a 52-week period. The primary endpoint of this global study is the change in FVC from baseline. Approximately 565 subjects will be enrolled. Subjects who complete the 52-week study may be eligible for rollover into a separate study offering open-label, extension treatment with pamrevlumab. For more information about the ZEPHYRUS study, please visit URL

FGEN FibroGen
$37.74

-0.03 (-0.08%)

05/29/19
GSCO
05/29/19
INITIATION
Target $45
GSCO
Neutral
FibroGen assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of FibroGen with a Neutral rating and $45 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $56 price target. Following the recent Phase 3 MACE safety results for roxadustat, the analyst sees the shares as range-bound pending further clarity from the FDA.
06/10/19
JEFF
06/10/19
NO CHANGE
Target $75
JEFF
Buy
FibroGen shares may rebound with FDA meeting feedback, says Jefferies
Jefferies analyst Michael Yee says his recent meeting with FibroGen management suggested the company's progress is well on track, with the FDA meeting soon. There could be more disclosure with an FDA agreement soon and a new drug application filing on time in Q3, which "should calm the Street," Yee tells investors in a research note. The analyst thinks the post-FDA meeting disclosure, confirmation of filing, and potentially more detailed data from Phase III could cause shares of FibroGen to rebound.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

PAYC

Paycom

$239.80

4.63 (1.97%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Upgrade
Paycom rating change  »

Paycom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

QCOM

Qualcomm

$87.95

-2.52 (-2.79%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Recommendations
Qualcomm analyst commentary  »

Qualcomm positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Breaking Hot Stocks news story on Target »

Target up 8.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AVY

Avery Dennison

$131.42

0.26 (0.20%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Avery Dennison to acquire Smartrac's RFID Inlay business for EUR225M »

Avery Dennison announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Earnings
Breaking Earnings news story on Target »

Target raises FY19 adj…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADSK

Autodesk

$164.53

2.08 (1.28%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Recommendations
Autodesk analyst commentary  »

Autodesk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:36
11/20/19
11/20
06:36
11/20/19
06:36
Earnings
Qiwi raises FY19 adjusted revenue growth view to 15%-19% from 9%-15% »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

TGT

Target

$110.86

0.27 (0.24%)

06:35
11/20/19
11/20
06:35
11/20/19
06:35
Earnings
Target sees Q4 adj. EPS $1.54-$1.75, consensus $1.65 

Sees Q4 SSS up 3%-4%.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$60.66

1.12 (1.88%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
TJX analyst commentary  »

Nomura Instinet lists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

T

AT&T

$38.00

-1.61 (-4.06%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
AT&T analyst commentary  »

KeyBanc data shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

LLY

Eli Lilly

$115.13

1.04 (0.91%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Hot Stocks
Eli Lilly to invest $400M in Indianapolis manufacturing facilities »

Eli Lilly announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

TGT

Target

$110.86

0.27 (0.24%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Target reports Q3 adj. EPS $1.36, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDXC

ChromaDex

$3.49

0.19 (5.76%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Hot Stocks
ChromaDex: EC votes in favor on Nicotinamide Riboside Chloride as a novel food »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Qiwi reports Q3 EPS 29c, one estimate 33c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:29
11/20/19
11/20
06:29
11/20/19
06:29
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

06:26
11/20/19
11/20
06:26
11/20/19
06:26
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.63

-0.295 (-4.98%)

06:24
11/20/19
11/20
06:24
11/20/19
06:24
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:22
11/20/19
11/20
06:22
11/20/19
06:22
Periodicals
WeWork began layoffs on Monday, Business Insider reports »

WeWork's layoffs…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Downgrade
Berry Petroleum rating change  »

Wells Fargo downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBCP

Concrete Pumping

$3.88

0.17 (4.58%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Conference/Events
Concrete Pumping management to meet with William Blair »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.03

-1.85 (-10.96%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Periodicals
Macy's confirms 'targeted data security incident' impacted customers, WSJ says »

Macy's says customer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AL

Air Lease

$45.16

0.435 (0.97%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Conference/Events
Air Lease management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Downgrade
Berry Petroleum rating change  »

KeyBanc downgrades Berry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XGN

Exagen

$19.25

-0.04 (-0.21%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Conference/Events
Exagen management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.